Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Inclusion Criteria

• •Age 18 to 65 years.
• •8/8 or 7/8 HLA-identical matched sibling OR Allele level 8/8 (HLA-A, B, C, DR Beta1)matched unrelated donor or 4/6 or better HLA matched cord blood.
• •Patients with high risk hematologic malignancies who are appropriate candidates for a myeloablative allogeneic stem cell transplantation.
• •Patients with a history of CNS disease must have been treated and have no active CNS disease at the time of protocol treatment.
• •ECOG performance status \< or equal to 2
• •Patients must have adequate function of other organ systems as measured by:
• •Creatinine clearance (by Cockcroft Gault equation) \> or equal to 30ml/min. Hepatic transaminases (ALT/AST) \< or equal to 4 x normal, bilirubin \< or equal to 2.0 mg/dl.
• •Pulmonary function tests demonstrating FVC and FEV1 of \> or equal to 50% of predicted for age and DLCO \> or equal to 50% of predicted.
• •Ejection fraction of \> or equal to 45% by echocardiogram, radionuclide scan or cardiac MRI.
• •Patients must be HIV negative.
• •Patients must not be pregnant.